Trump PEPFAR Review: Foreign Aid Impact
- Recent executive actions by the trump administration, including a foreign aid review and subsequent stop-work order, have significantly disrupted U.S.
- PEPFAR, authorized in 2003, represents the largest commitment by any nation to combat a single disease, operating in over 50 countries.
- A limited waiver issued in February allowed PEPFAR to continue "life-saving HIV services," such as treatment, prevention of mother-to-child transmission, and HIV testing.
Teh Trump administration’s recent actions, including a foreign aid review, have considerably impacted PEPFAR operations, potentially leading to increased HIV infections and deaths globally. funding freezes, USAID dissolution, and canceled awards are disrupting critical HIV treatment and prevention programs worldwide. PEPFAR, a program credited with saving millions of lives, now faces challenges due to these policy shifts. The stop-work order and proposed budget cuts threaten to reverse decades of progress in the fight against AIDS. Modeling studies predict dire consequences if the current disruptions continue. News Directory 3 has the latest updates on this ongoing crisis. Discover what’s next as the foreign aid review results are released and Congress considers reauthorizing PEPFAR.
PEPFAR Funding Cuts Disrupt HIV Programs Globally
Recent executive actions by the trump administration, including a foreign aid review and subsequent stop-work order, have significantly disrupted U.S. global health programs, notably the President’s Emergency Plan for AIDS Relief (PEPFAR).The actions included freezing payments, dissolving USAID, and canceling foreign assistance awards, impacting HIV treatment and prevention efforts worldwide.
PEPFAR, authorized in 2003, represents the largest commitment by any nation to combat a single disease, operating in over 50 countries. It’s credited with saving 26 million lives and preventing HIV infection in 7.8 million babies. The program has also spurred economic growth and improved childhood immunization rates.
A limited waiver issued in February allowed PEPFAR to continue ”life-saving HIV services,” such as treatment, prevention of mother-to-child transmission, and HIV testing. However, other crucial services, including prep for many at-risk individuals and programs for orphans, remain restricted. Implementers have faced challenges resuming programs and receiving payments.
The dissolution of USAID, which managed 60% of PEPFAR’s bilateral assistance in fiscal year 2023, has further hampered implementation. Reductions at the Centers for Disease Control and Prevention (CDC), another key implementing agency, could exacerbate the problem. Reports indicate that 86% of USAID awards have been canceled, including numerous HIV treatment and prevention initiatives.
A federal judge issued a preliminary injunction ordering the government to pay for completed work, but the court has not prevented the cancellation of awards. The administration notified Congress of its intent to permanently dissolve USAID, integrating its functions into the State Department.
The funding freeze has already led to staff layoffs, clinic closures, and disruptions in HIV testing and treatment services. UNAIDS reports the loss of thousands of health workers in several African countries and service disruptions in Ukraine and other regions. A WHO survey found that nearly half of its country offices reported moderate to severe disruptions to HIV services.
Modeling studies suggest that a 90-day funding pause could result in over 100,000 excess HIV-related deaths in sub-Saharan Africa. Ending PEPFAR entirely could lead to millions of new infections and AIDS-related deaths by 2030.
What’s next
The administration is expected to release the results of its foreign aid review, which could recommend further changes to PEPFAR. Congress may consider reauthorizing PEPFAR, possibly introducing program changes.The proposed dissolution of USAID and notable budget cuts for global health programs, including a $1.9 billion reduction for PEPFAR, also raise concerns about the future of HIV prevention and treatment efforts.